七十年结核病防治：疗效、效果、毒性、持久性和持续时间。
Seventy Years of Tuberculosis Prevention: Efficacy, Effectiveness, Toxicity, Durability, and Duration.
出版信息
Am J Epidemiol. 2019 Dec 31;188(12):2078-2085. doi: 10.1093/aje/kwz172.
Abstract
Tuberculosis (TB) has been a leading infectious cause of death worldwide for much of human history, with 1.6 million deaths estimated in 2017. The Department of Epidemiology at the Johns Hopkins Bloomberg School of Public Health has played an important role in understanding and responding to TB, and it has made particularly substantial contributions to prevention of TB with chemoprophylaxis. TB preventive therapy is highly efficacious in the prevention of TB disease, yet it remains underutilized by TB programs worldwide despite strong evidence to support its use in high-risk groups, such as people living with HIV and household contacts, including those under 5 years of age. We review the evidence for TB preventive therapy and discuss the future of TB prevention.
摘要
结核病（TB）在人类历史的大部分时间里一直是全球主要的传染病死因，据估计，2017 年有 160 万人死亡。约翰霍普金斯大学彭博公共卫生学院流行病学系在了解和应对结核病方面发挥了重要作用，特别是在化学预防结核病方面做出了特别重大的贡献。结核病预防性治疗在预防结核病发病方面具有很高的疗效，但尽管有强有力的证据支持在高危人群（如艾滋病毒感染者和包括 5 岁以下儿童在内的家庭接触者）中使用，但在全球结核病规划中仍未得到充分利用。我们回顾了结核病预防性治疗的证据，并讨论了结核病预防的未来。
相似文献
1
Seventy Years of Tuberculosis Prevention: Efficacy, Effectiveness, Toxicity, Durability, and Duration.七十年结核病防治：疗效、效果、毒性、持久性和持续时间。
Am J Epidemiol. 2019 Dec 31;188(12):2078-2085. doi: 10.1093/aje/kwz172.
2
[Development of antituberculous drugs: current status and future prospects].[抗结核药物的研发：现状与未来前景]
Kekkaku. 2006 Dec;81(12):753-74.
3
Global Epidemiology of Tuberculosis and Progress Toward Meeting Global Targets - Worldwide, 2018.全球结核病流行病学和实现全球目标的进展情况——2018 年全球范围
MMWR Morb Mortal Wkly Rep. 2020 Mar 20;69(11):281-285. doi: 10.15585/mmwr.mm6911a2.
4
TB preventive therapy for people living with HIV: key considerations for scale-up in resource-limited settings.在资源有限的环境下扩大 HIV 感染者的结核预防性治疗：主要考虑因素。
Int J Tuberc Lung Dis. 2018 Jun 1;22(6):596-605. doi: 10.5588/ijtld.17.0758.
5
Long time due: reducing tuberculosis mortality in the 21st century.逾期已久：降低21世纪的结核病死亡率
Arch Med Res. 2005 Nov-Dec;36(6):617-21. doi: 10.1016/j.arcmed.2005.06.002.
7
Prevention of tuberculosis in people living with HIV.预防 HIV 感染者中的结核病。
Clin Infect Dis. 2010 May 15;50 Suppl 3:S215-22. doi: 10.1086/651494.
8
Epidemiology of Tuberculosis and Progress Toward Meeting Global Targets - Worldwide, 2019.结核病流行病学和实现全球目标进展情况——2019 年全球范围。
MMWR Morb Mortal Wkly Rep. 2021 Mar 26;70(12):427-430. doi: 10.15585/mmwr.mm7012a4.
9
Preventive therapy for HIV-associated tuberculosis.HIV 相关结核病的预防治疗。
Curr Opin HIV AIDS. 2018 Nov;13(6):507-511. doi: 10.1097/COH.0000000000000504.
10
The Johns Hopkins Bloomberg School of Public Health: A Brief History of a Century of Epidemiologic Discovery.约翰霍普金斯大学彭博公共卫生学院：一个世纪流行病学发现简史。
Am J Epidemiol. 2016 Mar 1;183(5):340-4. doi: 10.1093/aje/kwv157. Epub 2016 Jan 27.
引用本文的文献
1
Investigating low uptake of tuberculin skin testing when integrated with active case-finding for TB.研究结核菌素皮肤试验与结核病主动病例发现相结合时的低接受率。
IJTLD Open. 2025 Mar 12;2(3):179-181. doi: 10.5588/ijtldopen.24.0667. eCollection 2025 Mar.
2
Rethinking latent TB? Think again.重新思考潜伏性结核病？还是再考虑考虑吧。
IJTLD Open. 2024 Aug 1;1(8):335-337. doi: 10.5588/ijtldopen.24.0336. eCollection 2024 Aug.
3
Effectiveness of preventive treatment among different age groups and Mycobacterium tuberculosis infection status: a systematic review and individual-participant data meta-analysis of contact tracing studies.不同年龄组和结核分枝杆菌感染状况下预防性治疗的有效性：一项接触者追踪研究的系统评价和个体参与者数据荟萃分析
Lancet Respir Med. 2024 Aug;12(8):633-641. doi: 10.1016/S2213-2600(24)00083-3. Epub 2024 May 8.
4
A case of oral tuberculous ulcer and literature review.1例口腔结核性溃疡病例及文献复习
Clin Case Rep. 2023 Dec 5;11(12):e8216. doi: 10.1002/ccr3.8216. eCollection 2023 Dec.
5
US Guidelines Fall Short on Short-Course Tuberculosis-Preventive Therapy.美国指南在短程结核病预防疗法方面存在不足。
Clin Infect Dis. 2024 Mar 20;78(3):514-517. doi: 10.1093/cid/ciad659.
6
High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus.高异烟肼暴露在每周一次利福喷汀治疗人类免疫缺陷病毒潜伏性结核中的情况。
Antimicrob Agents Chemother. 2023 Feb 16;67(2):e0129722. doi: 10.1128/aac.01297-22. Epub 2023 Jan 9.
7
Incidence of tuberculosis among PLHIV on antiretroviral therapy who initiated isoniazid preventive therapy: A multi-center retrospective cohort study.抗逆转录病毒治疗的 HIV 感染者中开始异烟肼预防治疗者的结核发病率：一项多中心回顾性队列研究。
PLoS One. 2022 May 16;17(5):e0266285. doi: 10.1371/journal.pone.0266285. eCollection 2022.
8
The need for effective drugs for TB prevention: set your goals high, and don´t stop till you get there.对有效结核病预防药物的需求：设定高远目标，不达目的誓不罢休。
Int J Tuberc Lung Dis. 2022 Feb 1;26(2):85-88. doi: 10.5588/ijtld.21.0736.
9
"If I've got latent TB, I would like to get rid of it": Derivation of the CARD (Constraints, Actions, Risks, and Desires) Framework informed by South African healthcare worker perspectives on latent tuberculosis treatment.如果我患有潜伏性结核病，我希望能够治愈它": 基于南非医护人员对潜伏性结核病治疗的观点得出的 CARD（约束、行动、风险和愿望）框架。
PLoS One. 2021 Aug 18;16(8):e0254211. doi: 10.1371/journal.pone.0254211. eCollection 2021.
10
A Randomized Controlled Trial of Isoniazid to Prevent Mycobacterium tuberculosis Infection in Kenyan Human Immunodeficiency Virus-Exposed Uninfected Infants.随机对照试验：异烟肼预防肯尼亚 HIV 暴露未感染婴儿结核分枝杆菌感染
Clin Infect Dis. 2021 Jul 15;73(2):e337-e344. doi: 10.1093/cid/ciaa827.
本文引用的文献
1
Improving Tuberculosis Preventive Therapy Uptake: A Cluster-randomized Trial of Symptom-based Versus Tuberculin Skin Test-based Screening of Household Tuberculosis Contacts Less Than 5 Years of Age.提高结核病预防治疗参与度：基于症状的与结核菌素皮肤试验的家庭接触者小于 5 岁的儿童结核病筛查的整群随机试验。
Clin Infect Dis. 2020 Apr 10;70(8):1725-1732. doi: 10.1093/cid/ciz436.
2
One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis.利福喷汀加异烟肼预防 HIV 相关结核病：一个月疗程。
N Engl J Med. 2019 Mar 14;380(11):1001-1011. doi: 10.1056/NEJMoa1806808.
3
Activity of a Long-Acting Injectable Bedaquiline Formulation in a Paucibacillary Mouse Model of Latent Tuberculosis Infection.长效注射贝达喹啉制剂在潜伏性结核感染小鼠模型中的活性。
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.00007-19. Print 2019 Apr.
4
Cost-effectiveness of universal isoniazid preventive therapy among HIV-infected pregnant women in South Africa.南非感染 HIV 的孕妇中普遍使用异烟肼预防治疗的成本效益。
Int J Tuberc Lung Dis. 2018 Dec 1;22(12):1435-1442. doi: 10.5588/ijtld.18.0370.
5
Maternal Motivation to Take Preventive Therapy in Antepartum and Postpartum Among HIV-Positive Pregnant Women in South Africa: A Choice Experiment.南非艾滋病毒阳性孕妇产前和产后采取预防治疗的动机：选择实验。
AIDS Behav. 2019 Jul;23(7):1689-1697. doi: 10.1007/s10461-018-2324-x.
6
Projected population-wide impact of antiretroviral therapy-linked isoniazid preventive therapy in a high-burden setting.在高负担地区，抗逆转录病毒治疗相关异烟肼预防性治疗的全人群影响预测。
AIDS. 2019 Mar 1;33(3):525-536. doi: 10.1097/QAD.0000000000002053.
7
Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults.成人潜伏性结核：利福平治疗 4 个月或异烟肼治疗 9 个月。
N Engl J Med. 2018 Aug 2;379(5):440-453. doi: 10.1056/NEJMoa1714283.
8
Safety and Side Effects of Rifampin versus Isoniazid in Children.利福平与异烟肼在儿童中的安全性和副作用。
N Engl J Med. 2018 Aug 2;379(5):454-463. doi: 10.1056/NEJMoa1714284.
9
Maternal priorities for preventive therapy among HIV-positive pregnant women before and after delivery in South Africa: a best-worst scaling survey.南非 HIV 阳性孕妇在分娩前后对预防治疗的优先考虑因素：最佳最差标度调查。
J Int AIDS Soc. 2018 Jul;21(7):e25143. doi: 10.1002/jia2.25143.
10
Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings.高负担环境中异烟肼与利福喷丁预防性治疗与单纯异烟肼预防结核病的成本效益比较。
Clin Infect Dis. 2018 Sep 14;67(7):1072-1078. doi: 10.1093/cid/ciy230.
Zotero 插件